Double-blind, randomized, placebo-controlled follow-up (n=364) assessing whether a single immediate postpartum IV infusion of low-dose esketamine (0.2 mg/kg) reduces incidence of maternal depression at 2 years postpartum in women with prenatal depressive symptoms.
This is a 2-year follow-up of a multicentre randomized, double-blind, placebo-controlled trial that administered a single immediate postpartum IV infusion of low-dose esketamine (0.2 mg/kg in 20 ml saline over ~40 minutes) to women with prenatal depressive symptoms.
The primary aim is to evaluate the incidence of maternal depression two years after delivery; preliminary 42-day results suggested reduced incidence with esketamine.
Outcomes include diagnostic assessments of depression at follow-up, safety and adverse events, and child developmental considerations described in the protocol.
Immediate postpartum intravenous infusion of low-dose esketamine (single infusion).
0.2 mg/kg in 20 ml normal saline infused at 30 ml/h over ~40 minutes postpartum
Immediate postpartum intravenous infusion of normal saline (single infusion).
20 ml normal saline infused at 30 ml/h over ~40 minutes postpartum